4//SEC Filing
Kollins John A 4
Accession 0000899243-23-014879
CIK 0001692830other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 4:31 PM ET
Size
21.9 KB
Accession
0000899243-23-014879
Insider Transaction Report
Form 4
Kollins John A
DirectorPresident and CEO
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-06-08−505,000→ 0 totalExercise: $3.46→ Common Stock (505,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-06-08−127,659→ 0 totalExercise: $0.90→ Common Stock (127,659 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-06-08−175,000→ 0 totalExercise: $29.00→ Common Stock (175,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-06-08−276,595→ 0 totalExercise: $4.56→ Common Stock (276,595 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-06-08−127,659→ 0 totalExercise: $0.90→ Common Stock (127,659 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-06-08−240,000→ 0 totalExercise: $4.60→ Common Stock (240,000 underlying) - Disposition from Tender
Common Stock, $0.0001 par value
2023-06-06$0.91/sh−305,911$278,379→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2023-06-08−127,659→ 0 totalExercise: $1.04→ Common Stock (127,659 underlying)
Footnotes (3)
- [F1]Disposed of to SNBL23 Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("Parent"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock at a purchase price of $0.91 per share and one non-transferable contractual contingent value right (the "Offer Price").
- [F2]Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
- [F3]Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.
Documents
Issuer
Satsuma Pharmaceuticals, Inc.
CIK 0001692830
Entity typeother
Related Parties
1- filerCIK 0001391070
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 4:31 PM ET
- Size
- 21.9 KB